William Blair and MaidStone Life Sciences Biotech Focus Conference

Day One –

12^th Annual Cancer Immunotherapy Conference

8:00 a.m.

Keynote I: Physicians View of the Challenges and Unmet Needs in Cell Therapies

Matthew Frigault, M.D.

Administrative Director, Cellular Therapy Service

Assistant Professor of Medicine, Harvard Medical School

8:30 a.m.

Q&A

8:45 a.m.

Break

8:55 a.m.

Panel I: Preparing for Launch: Navigating the Regulatory Landscape and Operationalizing Cell Therapies

(Raj moderating)

Participating Companies:

Allogene Therapeutics, Inc. (ALLO)

Eric Schmidt, Ph.D.

CFO

Autolus Therapeutics, Ltd. (AUTL)

Christian Itin, Ph.D.

CEO

Arcellx, Inc. (ACLX)

Rami Elghandour

CEO

Obsidian Therapeutics (private)

Paul Wotton, Ph.D.

CEO

Affini-T Therapeutics, Inc. (private)

Jak Knowles, M.D.

Co-founder, President & CEO

10:15 a.m.

Break

10:25 a.m.

Keynote II: Engineering T-Cells for Enhanced Immunotherapy of Solid Tumors

Michael C. Milone, M.D., Ph.D.

Assistant Professor of Pathology and Laboratory Medicine at the Hospital of University of Pennsylvania

Associate Director, Toxicology Laboratory

University of Pennsylvania Perelman School of Medicine

10:55 a.m.

Q&A

11:05 a.m.

Break

11:15 a.m.

Panel II: Off The shelf: Next-Generation Allogeneic Cell Therapies

(Sami Moderating)

Participating Companies:

Nkarta, Inc. (NKTX)

Paul Hastings

CEO

Poseida Therapeutics, Inc. (PSTX)

Mark Gergen

CEO

Wugen, Inc. (private)

Dan Kemp, Ph.D.

CEO

Century Therapeutics, Inc. (IPSC)

Lalo Flores, Ph.D.

CEO

Beam Therapeutics, Inc. (BEAM)

John Evans

CEO

12:15 p.m.

Lunch

1:00 p.m.

.

Keynote III: Multispecific Protein Therapies: Where we’ve Been and Where We’re Going?

Patrick Baeuerle, Ph.D.,

Co-founder and Acting Chief Scientific Officer

Cullinan Oncology

Executive Partner, MPM Capital

1:30 p.m.

Q&A

1:40 p.m.

Break

1:50 p.m.

Panel III: Moving Beyond Monoclonals: The Potential of Multispecific Therapies

(Phipps moderating)

Participating Companies:

Immunocore Holdings Plc (IMCR)

Bahija Jallal, Ph.D.

CEO

Merus N.V. (MRUS)

Bill Lundberg, M.D.

CEO, Principal Financial Officer

Pieris Pharmaceuticals, Inc. (PIRS)

Steve Yoder

CEO

TRIO Pharmaceuticals, Inc. (private)

Reiner Laus, M.D.

CEO and Co-founder

3:10 p.m.

Break

3:20 p.m.

Keynote IV: Clinical Trial Considerations for Biology Informed Immuno-Oncology Drug Development

TBD

3:50 p.m.

Q&A

4:00 p.m.

Break

4:10 p.m.

Panel IV: Developing Therapies for the Next Immuno-Oncology Targets

(Phipps moderating)

Participating Companies:

Agenus, Inc. (AGEN)

Steven O’Day, M.D.

CMO

Codiak BioSciences, Inc. (CDAK)

Doug Williams, Ph.D.,

CEO

Tempest Therapeutics, Inc. (TPST)

Tom Dubensky, Ph.D.,

President

Hibercell, Inc. (private)

Alan Rigby, Ph.D.
President & CEO

5:20 p.m.

Closing Remarks

Day Two

Key Topics in Biotech

Panel Discussions

9:00 a.m.

Panel 1: Next Generation Small Molecules in Oncology

Ikena Oncology, Inc. (IKNA)

Mark Manfredi, Ph.D.

President & CEO

Kinnate Biopharma, Inc. (KNTE)

Nima Farzan

CEO

Immuneering Corp. (IMRX)

Benjamin Zeskind, Ph.D.

Co-Founder, President and CEO

9:45 a.m.

Break

10:00 a.m.

Panel 2: AAV Gene Therapy: Delivery and Beyond

Taysha Gene Therapies, Inc. (TSHA)

RA Session II

President, Founder & CEO

Renovacor, Inc. (RCOR)

Magdalene Cook, Ph.D.

President & Chief Executive Officer

10:45 a.m.

Break

11:00 a.m.

Panel 3: Developing Therapies Against Novel Targets in Autoimmune Diseases

Kezar Life Sciences, Inc (KZR)

Noreen Roth Henig, M.D.,

CMO

Aclaris Therapeutics, Inc. (ACRS)

Neal Walker, D.O.

President & CEO

Nimbus Therapeutics (Private)

Jeb Keiper

Chief Executive Officer

Ventus Therapeutics, Inc. (Private)

Michael Crackower, Ph.D.,

CSO

11:45 a.m.

Break

12:00 p.m.

Panel 4: Unmet Needs and Novel Therapies in Neuropsychiatry

Axsome Therapeutics, Inc. (AXSM)

Herriot Tabuteau, MD

CEO

VistaGen Therapeutics, Inc. (VTGN)

Shawn Singh, J.D.

CEO

Bionomics Limited (BNOX)

Errol De Souza, Ph.D.

Executive Chairman

12:45 p.m.

Break

1:00 p.m.

Panel 5: There And Back Again, Dawn Of A New Era in Radiopharmaceuticals

Point Biopharma Global Inc.

Joe McCann, Ph.D.

President & CEO

Fusion Pharmaceuticals Inc.

John Valliant, Ph.D.

Founder & CEO

Aktis Oncology, Inc.

Matthew Roden, Ph.D.

President & CEO

Telix Pharmaceuticals Ltd.

Chris Behrenbruch, DPhil, J.D., MBA

Group Managing Director and CEO

1:45 p.m.

Break

2:00 p.m.

Panel 6: Novel Modalities and Delivery for RNA-Targeted Therapeutics

Ionis Pharmaceuticals, Inc. (IONS)

Brett Monia, Ph.D.

CEO

Silence Therapeutics, plc (SLN)

Craig Tooman

CEO

ReCode Therapeutics, Inc.

David Lockhart, Ph.D.

President and CSO

Locanabio, Inc.

Jim Burns, Ph.D.

CEO

2:45 p.m.

Break

3:00 p.m.

Panel 7: Developing Genomic Medicines

Generation Bio Co.

Geoff McDonough, M.D.

President and CEO

Arbor Biotechnologies

Devyn Smith, Ph.D.

CEO

Design Therapeutics, Inc.

João Siffert, M.D.

President and CEO

Verve Therapeutics, Inc.

Sekar Kathiresan, M.D.

Co-founder and CEO

Metagenomi, Inc.

Simon Harnest

Chief Investment Officer and SVP of Strategy